Abbott Hopes To Prevent Heart Failure Hospitalizations With New CardioMEMS HF Labeling
Executive Summary
The FDA expanded the indication for Abbott’s CardioMEMS HF wireless heart failure monitor to include patients who have never been hospitalized for heart failure before.
You may also be interested in...
Exec Chat: Abbott Wants to Identify Heart Failure Patients Earlier
Abbott executives Philip B. Adamson and Robert Kormos talked to Medtech Insight about how the company is trying to slow the progression of heart failure and reduce heart failure hospitalizations.
Abbott Seeks Expanded Labeling For CardioMEMS HF Monitor Based On GUIDE HF Results
The GUIDE HF investigators contend the trial missed its primary endpoint because of COVID-19.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.